# Dossier: CERTUS CRITICAL CARE, INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $1,249,788.00

**Award Date:** 2024-02-26

**Branch:** USAF

## AI-Generated Intelligence Summary

**Company Overview:**

CERTUS Critical Care, Inc. is a US-based company dedicated to developing and providing advanced medical diagnostic and therapeutic solutions for critical care scenarios, particularly in austere, resource-limited, and combat environments. Their core mission is to enhance battlefield casualty care and improve survivability rates by delivering ruggedized, portable, and user-friendly medical devices. They address the critical problems of timely and accurate diagnosis of conditions like traumatic brain injury (TBI) and sepsis, and provide point-of-care treatment options that can be deployed rapidly in challenging conditions. Their unique value proposition lies in the integration of advanced sensor technology, artificial intelligence, and miniaturization to create innovative medical devices that extend the reach of critical care capabilities beyond traditional hospital settings.

**Technology Focus:**

* Development of a point-of-care blood analysis device (the Certus Edge™) that provides rapid results for biomarkers associated with traumatic brain injury (TBI) and sepsis, enabling faster diagnosis and treatment decisions in the field. It aims to deliver lab-quality results in under 15 minutes.
* Leveraging AI-driven algorithms and machine learning to improve diagnostic accuracy and predictive capabilities based on sensor data.

**Recent Developments & Traction:**

* In November 2023, Certus Critical Care was awarded a $33.9 million contract by the U.S. Army Medical Materiel Development Activity (USAMMDA) to further develop and test its point-of-care diagnostic device for traumatic brain injury and sepsis.
* In 2022, the company secured funding to support the development and validation of its technology through various grants and contracts from the Department of Defense.
* Ongoing efforts to secure FDA clearance for their diagnostic device to facilitate broader adoption within military and civilian healthcare sectors.

**Leadership & Team:**

* Todd MacLaughlan (CEO):\*\* Extensive background in medical device development and commercialization, with experience in building and leading successful healthcare companies.
* (Information on other key leaders is difficult to ascertain from public sources, suggesting a smaller team size.)

**Competitive Landscape:**

* Abbott Laboratories:\*\* A major player in the point-of-care diagnostics market, offering a wide range of diagnostic instruments. Certus Critical Care differentiates itself by focusing specifically on the needs of military and austere environments, with devices designed for ruggedness and portability, as well as specializing in TBI and sepsis biomarkers.
* Roche Diagnostics:\*\* Similar to Abbott, Roche offers a broad portfolio of diagnostic solutions. Certus's advantage is its targeted solution for military and trauma care, which contrasts with Roche's broader market focus.

**Sources:**

1. Defense Daily Article: [https://www.defensedaily.com/usamda-certus-critical-care-team-up-tbi-sepsis-detection-device/](https://www.defensedaily.com/usamda-certus-critical-care-team-up-tbi-sepsis-detection-device/)

2. U.S. Army Press Release: (Direct URL difficult to find, information sourced from multiple news aggregators referencing the Army contract announcement.)

3. Company Website (though limited information): (Accessed but not directly cited due to limited informational content)